eTurboNews - Independent and Global Travel, Tourism, Lifestyle, Entertainment News you only find here

Travel News Distribution powered by eTurboNews:

Skinvisible to Present at 5th International Bird Flu Summit

Skinvisible to Present at 5th International Bird Flu Summit ( WHO Officials and International Pandemic Scientists to Present
Las Vegas, Nevada - September 18, 2007 - Skinvisible, Inc. (OTC Bulletin Board: SKVI / Website:, the developers of Invisicare®, a patented polymer delivery system for topical dermatology products, is pleased to announce its participation as a Gold Sponsor in the Fifth International Bird Flu Summit being held in Las Vegas, NV.

Skinvisible will be a presenter at the Summit, highlighting its new Chlorhexidine antimicrobial hand-sanitizing lotion; DermSafe™, which has clinical studies showing a greater than 99.9% kill / inactivation of the avian bird flu virus (H5N1), an effect lasting up to four hours. Further findings will be presented at the Summit by Dr. Rob Lambkin-Williams, Managing Director from Retroscreen Virology, a subsidiary of the University of London's Queen Mary School of Medicine, at 2:45 PM on September 27th.

“Skinvisible is thrilled to have access to the key international pandemic decision-makers from pharmaceutical companies and government agencies at this Summit," said Mr. Terry Howlett, President and CEO of Skinvisible. “As our objective is to obtain further international government approvals as well as find international licensees for our product, this is a great opportunity to have DermSafe highlighted to this influential audience."

The Summit will be held on September 27-28 at the Thomas&Mack Convention Center. The theme of the Summit is to help the world effectively respond to the threat of a bird flu pandemic. International experts are slated to speak on various topics regarding this subject. Delegates from around the world will be attending. For more information about the Summit and the bird flu, go to:
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals, a wholly owned subsidiary of Skinvisible Inc., is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the patent.
About Invisicare®
Invisicare is a patented polymer delivery system developed to hold active ingredients topically on the skin for extended periods of time. A key benefit is that Invisicare is non-occlusive on the skin, allowing normal skin respiration and perspiration. The Company has developed a portfolio of topical products using Invisicare for the dermatology and cosmeceutical industries.
Forward-Looking Statements
This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending June 30, 2007)
Skinvisible and Invisicare are registered trademarks of Skinvisible Pharmaceuticals, Inc.
More information at: |

Terry Howlett, President/CEO Skinvisible Pharmaceuticals, Inc Phone: 702-433-7154 Email:

+++ Upload Your Press Release +++

Need assistance?

You need a little assistance?Call for help

Subscribe Now!

News Distribution Service

Distribute your press release with our service?

Submit Your Press-release

Latest Travel News